Aurinia Pharmaceuticals (NASDAQ:AUPH) specializes in the development and commercialization of therapies aimed at treating targeted patient populations suffering from serious diseases with a high unmet medical need. Its primary focus is on autoimmune diseases, particularly in the realm of nephrology and autoimmunity. A key project for Aurinia is its innovative drug, voclosporin, designed specifically for the treatment of lupus nephritis, a severe and potentially life-threatening condition. The objective of Aurinia is to achieve breakthroughs in patient care by advancing these treatments through rigorous clinical trials and regulatory pathways, aiming to bring new hope and therapeutic options to patients and healthcare providers worldwide.